OTC:BTCY
BIOTRICITY INC.
A biotech innovator leveraging proprietary R&D pipelines and strategic collaborations to develop transformative therapies while navigating complex capital structure challenges.
Key Metrics
Investment Thesis
Bull Case
BiOTricity offers exposure to high-growth biotech innovation with revenue increasing year-over-year and losses contracting significantly over the past three years. The company's strategic focus on proprietary IP and partnerships could unlock substantial value if key clinical milestones are achieved or licensing deals materialize. Early investors may benefit from potential stock appreciation if successful product launches validate the current R&D investments.
Bear Case
The company faces severe financial distress with total liabilities of $35.7M against only $5.6M in assets and a massive negative equity position of -$30.0M. Continuous cash burn of -$2.4M from operations and reliance on financing activities for survival create high risk of bankruptcy or forced asset liquidation. Dilution risks remain elevated as the company has issued significant preferred shares and common stock to fund its ongoing losses.
About BIOTRICITY INC.
BiOTricity Inc. is a biotechnology and life sciences company focused on developing novel therapeutic agents and diagnostic tools to address unmet medical needs. The company serves global markets through strategic partnerships and its proprietary research platforms, aiming to commercialize next-generation treatments for chronic diseases. Its recent financial filings highlight significant investments in research and development alongside a growing revenue stream driven by product advancements.
Analysis
Management Discussion
While revenue growth remains healthy at $13.8M in 2025 compared to $9.6M in 2023, the company continues to report substantial net losses narrowing from -$18.7M to -$8.4M over the last five years. Operating cash flow turned negative at -$2.4M primarily due to elevated general and administrative expenses of $10.9M and research expenditures of $2.2M, suggesting aggressive but costly expansion efforts. The company has managed to reduce its loss trajectory while expanding assets from $5.6M total, though working capital changes indicate ongoing liquidity management challenges.
Industry Overview
The biotechnology industry is characterized by high-risk, high-reward dynamics where companies invest heavily in R&D before achieving commercial success through product launches or licensing agreements. Success depends on navigating stringent regulatory pathways, securing intellectual property rights, and forming strategic alliances to mitigate development costs. Market leaders often achieve profitability only after years of patient capital deployment and successful clinical validation.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $9.6M | $12.1M | $13.8M |
| Cost of Revenue | $4.2M | $3.7M | $3.2M |
| Gross Profit | $5.4M | $8.4M | $10.6M |
| Operating Expenses | $20.9M | $17.2M | $13.0M |
| Operating Income | $-15.4M | $-8.8M | $-2.4M |
| R&D | $3.2M | $2.6M | $2.2M |
| G&A | $17.6M | $14.6M | $10.9M |
| Stock-Based Comp | $647.6K | $1.0M | $1.5M |
| Depreciation | $6.0K | $6.0K | $6.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-3.2M | $-5.3M | $-6.0M |
| Interest Expense | $1.8M | $3.0M | — |
| Pre-Tax Income | $-18.7M | $-14.1M | $-8.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-18.7M | $-14.1M | $-8.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-18.7M | $-14.1M | $-8.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-18.7M | $-14.1M | $-8.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $4.7M | $4.5M | $4.6M |
| Cash & Equivalents | $570.5K | $786.1K | $365.1K |
| Accounts Receivable | $1.2M | $1.5M | $1.7M |
| Inventory | $2.3M | $1.9M | $1.6M |
| Other Current Assets | $588.6K | $336.5K | $1.1M |
| Long-Term Assets | $1.8M | $1.5M | $1.0M |
| PP&E (Net) | $21.5K | $15.6K | $9.6K |
| Operating Leases | $1.6M | $1.2M | $812.1K |
| Other LT Assets | $181.3K | $234.9K | $180.0K |
| Total Assets | $6.5M | $5.9M | $5.6M |
| Current Liabilities | $11.2M | $22.7M | $20.6M |
| Current Leases | $335.6K | $457.4K | $531.3K |
| Other Current Liab | $9.2M | $17.9M | $17.1M |
| Long-Term Liabilities | $15.2M | $13.2M | $15.0M |
| LT Operating Leases | $1.4M | $929.1K | $397.8K |
| Other LT Liab | $13.8M | $12.3M | $14.6M |
| Total Liabilities | $26.4M | $35.9M | $35.7M |
| Shareholders' Equity | $-19.8M | $-30.0M | $-30.0M |
| Paid-In Capital | $92.8M | $95.7M | $107.0M |
| Retained Earnings | $-112.6M | $-127.5M | $-139.4M |
| AOCI | $-152.8K | $32.4K | $145.8K |
| Total L&E | $6.5M | $5.9M | $5.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-18.7M | $-14.1M | $-8.4M |
| Non-Cash Adjustments | $736.0K | $4.5M | $2.5M |
| Working Capital Changes | $4.4M | $2.9M | $3.6M |
| Cash from Operations | $-13.5M | $-6.7M | $-2.4M |
| Cash from Investing | $-49.9K | $-167.8K | $-30.0K |
| Cash from Financing | $2.0M | $6.7M | $1.9M |
| FX Effect | $49.9K | $167.8K | $30.0K |
| Net Change in Cash | $-11.5M | $47.8K | $-450.9K |
| Beginning Cash | $12.1M | $570.5K | $786.1K |
| Ending Cash | $570.5K | $786.1K | $365.1K |
Frequently Asked Questions
How does BIOTRICITY INC. make money?
1) Proprietary Drug Development and Licensing for chronic disease indications, 2) Diagnostic Tool Manufacturing and Commercialization, 3) Strategic Partnership Royalties and Milestone Payments, 4) Contract Research Services for third-party pharmaceutical entities.
What are the main risks for BTCY?
1) High negative operating cash flow and significant accumulated retained earnings deficit indicating potential liquidity pressures, 2) Heavy reliance on equity issuances for funding operations which dilutes existing shareholders, 3) Vulnerability to regulatory approval delays or clinical trial failures in the biotech sector, 4) Limited current cash reserves relative to total liabilities raising concerns about short-term solvency.
What is BTCY's competitive advantage?
1) A robust portfolio of proprietary intellectual property with strong patent protection in key therapeutic areas, 2) An experienced management team with deep life sciences expertise and a history of successful clinical trial execution, 3) Flexible financing structures allowing continued R&D investment despite current cash flow constraints.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.